CANbridge Pharmaceuticals Inc.: CANbridge CAN106 Phase 1 Data Presented at the European Hematology Association 2022 Congress

Rapid and potent C5 inhibition achieved with complete and sustained blockage of complement by a single dose of CAN106 Data to be presented at the 14th International Conference on Complement

Related Keywords

China ,National University Hospital ,Singapore General ,Singapore ,Austria ,Vienna ,Wien ,Greece ,Gerry Cox ,Geraldf Cox ,Chin Meng Khoo ,James Xue ,Qizhen Wu ,Chris Brinzey ,European Hematology Association Congress ,University Of Massachusetts Medical School Umass ,European Hematology Association ,Planet Communications ,Monoclonal Antibody In Clinical Development ,Development Strategist ,Canbridge Pharmaceuticals Inc ,Canbridge Pharmaceuticals ,Department Of Medicine ,Clinical Development ,International Conference On Complement Therapeutics ,International Conference ,Hematology Association Congress ,Complement Therapeutics ,Chief Development Strategist ,Interim Chief Medical Officer ,Ascending Dose Study ,Long Acting Anti C ,Monoclonal Antibody ,Charlene Song ,Medical Affairs ,Wuxi Biologics ,Massachusetts Medical School ,Pharmaceuticals Inc ,Canbridge ,Pharmaceuticals ,An106 ,Hase ,Data ,Resented ,European ,Hematology ,Association ,022 ,Congress ,